Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Hepatitis B Virus
Research on hepatitis B virus detailed by L.J. Braun and co-authors
February 11th, 2009
According to recent research published in the journal Vaccine, "Vaccines containing aluminum salt adjuvants are prone to inactivation following exposure to freeze-thaw stress. Many are also prone to inactivation by heat." "Thus, for maximum potency, these vaccines must be maintained at temperatures between 2 degrees C and 8 degrees C which requires the use of the cold chain. Nevertheless, the cold chain is not infallible. Vaccines are Subject to freezing during both transport and storage, and frozen vaccines are discarded uinder the best circumstances) or inadvertently administered despite potentially reduced potency. Here we describe an approach to minimize our...
Source: Vaccine Weekly (2009-02-11)
|
